Dr. Ali Damavandy is a board-certified dermatologist who specializes in skin cancer surgery, including Mohs micrographic surgery and the subsequent reconstruction. He underwent rigorous fellowship training in Mohs micrographic surgery, dermatological oncology and procedural dermatology at one of the most prestigious programs in the country at the University of Pennsylvania in Philadelphia, PA.
He was accepted into the accelerated 7-year BA/MD program at George Washington University, earning a bachelor of science degree in biology, summa cum laude, with a 4.0 GPA and graduating as the valedictorian of his medical school class. Dr. Ali Damavandy completed his internship in internal medicine at Harvard Medical School’s Beth Israel Deaconess Medical Center in Boston, MA, and his residency in dermatology at Georgetown University Hospital in Washington, D.C., where he served as Chief Resident in his final year.
He is a member of the Phi Beta Kappa, Alpha Omega Alpha, and Gold Humanism Medical Honor Societies. He is also a member of the American Academy of Dermatology, American Society for Dermatologic Surgery and the American College of Mohs Surgery. He has served in national leadership positions for the field of dermatology, authored several manuscripts for peer-reviewed journals and book chapters, and lectures nationally on the topics of cutaneous oncology and reconstructive surgery.
Dr. Ali Damavandy is passionate about preventing and curing skin cancer in a gentle and compassionate manner. He is dedicated to helping his patients, educating them about their condition and offering them world-class medical, surgical and cosmetic dermatology care.
Dr. Damavandy practices at our Annapolis, Maryland office.
Basal Cell Carcinoma, also known as basalioma or basal cell cancer, is the most common type of skin cancer and carries the least amount of risk, though it still requires attention. If caught and treated early, basal cell carcinomas are not likely to be life-threatening, but they do have the potential to cause disfigurement of the skin tissue.
Almost one million new cases of basal cell carcinoma are diagnosed each year in the U.S., and up to 30% of Caucasians may develop basal cell carcinomas in their lifetime.
Skin cancer is considered low risk when the affected cells remain clustered in a single group. Both basal cell carcinoma and squamous cell carcinoma are rarely life-threatening. Though it is unlikely to spread to other parts of your body, if left untreated, basal cell carcinoma can move into nearby bone or other tissue.
Basal cell carcinoma typically begins as a small, shiny bump on the face, although it can occur on any part of the body.
Melanoma, the deadliest of skin cancers, only accounts for about 4 percent of all skin cancer cases, but causes about 79 percent of skin cancer deaths.
Melanoma is a cancer of the skin that begins in the melanocytes, which are the cells that produce the pigment melanin. It is the leading cause of cancer death in women 25 to 30 years old and the second leading cause of cancer death in women 30 to 35 years old.
In some cases, melanoma occurs in melanocytes throughout the body, even if those parts have never been exposed to the sun.
Mohs surgery offers the highest cure rates for all non-melanoma skin cancers. For certain cases of the most common types of skin cancer — squamous cell carcinoma and basal cell carcinoma — the cure rate can be as high as 99 percent.
Mohs surgery is a highly specialized surgical technique used to treat non-melanoma skin cancers in which the surgeon removes all of the visible cancer, plus a small margin of the surrounding healthy tissue and examines it to ensure that all cancer cells have been removed at the time of surgery.
During Mohs micrographic surgery — named after Dr. Frederic Mohs, who first performed it in the 1930s — cancer is removed from the skin layer by layer until all cancerous cells have been removed. This type of surgery is most commonly used for cancers that have a high risk of re-occurrence. This technique allows for complete removal of the skin cancer while minimizing the removal of surrounding healthy skin.
Skin cancer is the most common form of cancer in the U.S. with more than 3.5 million cases diagnosed each year.
Skin cancer is the result of uncontrolled growth of abnormal skin cells that takes place when skin cells suffer DNA damage and then mutate, causing them to multiply rapidly and form malignant (cancerous) tumors. Most skin cancers develop on the visible outer layer of the skin (the epidermis), particularly on sun-exposed areas such as the face, head, hands, arms and legs. They are usually easy to detect with a skin examination, which increases the chances of early diagnosis.
There are different types of skin cancer, each named for the type of skin cell from which they originate. The most common type of skin cancer is basal cell carcinoma. Almost one million new cases of basal cell carcinoma are diagnosed each year in the U.S. Most skin cancers fall into one of three categories:
There are often warning signs that cancer is developing. The most common are pre-cancerous lesions called actinic keratoses that often develop on sun-exposed areas. These tumors replace normal surrounding tissue and generally do not spread to other areas.
Skin cancer is considered low risk when the affected cells remain clustered in a single group. Both basal cell carcinoma and squamous cell carcinoma are rarely life-threatening.
Skin cancer is considered a high risk when cells have invaded surrounding tissues. The third most common skin cancer, malignant melanoma, can be life-threatening if not diagnosed and treated early.
If skin cancer is detected before it has spread to surrounding tissues, the chances of a complete recovery and cure are excellent. High-risk forms of cancer like melanoma require more aggressive treatments.
Squamous Cell Carcinoma is a common form of skin cancer that develops in the squamous cells that make up the outer layer of the skin. Although it is usually not life-threatening, it can be aggressive in some cases.
If left untreated, squamous cell carcinoma can grow large or spread to other parts of your body, causing serious complications.
Atypical moles, also known as dysplastic nevi, are unusual-looking benign (noncancerous) moles.
A dysplastic mole is one that, when viewed on a cellular level, has features unlike those of a healthy, benign mole. A benign mole will have a regular pattern of coloration and pigment, even borders, symmetry, and a tan or pink color. Dysplastic moles can be asymmetric, have indistinct borders, or contain multiple colors or very dark pigment.
Dysplastic moles are often spotted as the “ugly duckling” on a patient’s skin. Any departure from the typical mole a person’s skin makes may be dysplastic. They can appear anywhere on the body, but in most cases are found on the back, chest, buttocks, breasts, or scalp.